In Brief: Hexagen
Executive Summary
Hexagen: First round funding raises $6.2 mil. for the Cambridge, England-based functional genomics company. Abingworth Management, New Enterprise Associates and Schroder Ventures participate. Hexagen will use proceeds to establish operations. Hexagen's proprietary technology enables the company "to quickly produce variants in any gene for which the DNA sequence is known, enabling the function of that gene to be studied." Hexagen is led by CEO Mark Bodmer, PhD, formerly Celltech director of biology, and President Andrew Sandham, previously Roche U.K. business development director and Cantab chief operating officer...